Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02845791
Other study ID # 65436
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 2016
Est. completion date October 2017

Study information

Verified date January 2019
Source University Hospitals, Leicester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To investigate whether the interactive family based lifestyle programme leads to behaviour change at 6 months with the primary outcome being increased levels of moderate to vigorous physical activity (MVPA).


Description:

To investigate whether the lifestyle programme results in changes to the following outcomes 3 and 6 months after baseline assessment (Child)

- An increase in objectively measured total amount of physical activity

- An increase in the proportion meeting MVPA guidelines (measured objectively)

- Reduction in time spent sedentary (measured objectively and self-reported)

- Change in self-reported physical activity

- Reduction in measures of adiposity (body mass index percentile, per cent body fat)

- Improvement in psychological factors that may mediate physical activity participation (self-efficacy, motivation, attitudes, social support and enjoyment of physical activity; and physical self-perceptions)

- Change in healthy food provision and parenting practices for healthy food

- Improvement in diet composition.

- Improvement in knowledge of physical activity and nutrition.

- Improvement in cardio-metabolic variables (blood pressure, glucose, HbA1c, cholesterol)

The Investigators will also include qualitative data collected from:

- Evaluation forms following each intervention workshop session which will be completed by the Parent/guardian, child and facilitator

- Feedback from focus groups to be held following completion of the total intervention i.e. 8 sessions

To investigate whether the lifestyle programme results in changes to the following outcomes 3 and 6 months after baseline assessment (Parent(s)/guardian(s))

- An increase in objectively measured total volume of physical activity

- An increase in the proportion meeting MVPA guidelines (measured objectively)

- Reduction in time spent sedentary (measured objectively and self-reported)

- Change in self-reported physical activity

- Reduction in measures of adiposity (body mass index percentile, per cent body fat)

- Change in healthy food provision and parenting practices for healthy food

- Improvement in diet composition.

- Improvement in knowledge of physical activity and nutrition.


Recruitment information / eligibility

Status Completed
Enrollment 318
Est. completion date October 2017
Est. primary completion date March 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years to 14 Years
Eligibility Inclusion Criteria:

Parents/guardians will answer questions in the eligibility questionnaire about their child and family health history. Participants will be invited to participate if they are 12-14 years old inclusive (12 years 0 days to 14 years 354 days old) and are identified as having the following risk factors for development of Type 2 Diabetes (which will be identified from the eligibility questionnaire):

BMI > 95th percentile for age and gender OR

BMI > 85th percentile PLUS one other from the following list:

- Family history of Diabetes (first degree relative).

- Non-white ethnicity.

- Watching TV/play computer games for more than 2 hours a day (self-report).

- Sugar intake more than 1.5 cans (or 532 ml) of fizzy pop/fruit juice per day (self-report).

Exclusion Criteria:

Young people will not be eligible for participation in the study if they are outside the age range of interest (<11 years and 364 days or >14 years and 1 day), have an existing diagnosis of Type 1 or Type 2 Diabetes, < 85th percentile. Young people will also be excluded if they themselves do not provide written assent or their parent/guardian does not provide written consent.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Interactive Lifestyle programme workshop
Participants will attend eight 90 minute sessions of an interactive lifestyle programme along with their parent(s)/guardian(s).

Locations

Country Name City State
United Kingdom University Hospitals of Leicester Leicester

Sponsors (11)

Lead Sponsor Collaborator
University Hospitals, Leicester Alexander Technological Educational Institute, Thessaloniki, Greece, Associacao Protectora dos Diabeticos de Portugal, Basque Government Department of Public Health, Diabetes Centre of Paediatrics P&A, Health Department of the Alto/Bajo Deba, Spain, Primary Care Centre Egia, San Sebastian, Spain, Technische Universität Dresden, The Algarve Regional Health Administration, University of Leicester, University of Leipzig

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint is to detect a change in objectively measured MVPA of 10 minutes per day within the intervention group at 6 months. Participating children and adults will be asked to wear the wrist worn GENEActiv accelerometer (ActivInsights, Kimbolton, Cambridgeshire, UK) continuously for up to 8 days. 6 months post baseline
Secondary An increase in total volume of physical activity Participating children and adults will be asked to wear the wrist worn GENEActiv accelerometer (ActivInsights, Kimbolton, Cambridgeshire, UK) continuously for up to 8 days. 3 and 6 months
Secondary An increase in the proportion meeting MVPA guidelines Participating children and adults will be asked to wear the wrist worn GENEActiv accelerometer (ActivInsights, Kimbolton, Cambridgeshire, UK) continuously for up to 8 days. 3 and 6 months
Secondary Reduction in time spent sedentary Participating children and adults will be asked to wear the wrist worn GENEActiv accelerometer (ActivInsights, Kimbolton, Cambridgeshire, UK) continuously for up to 8 days. 3 and 6 months
Secondary Change in physical activity levels Self reported - questionnaire 3 and 6 months
Secondary Reduction in Body mass index percentile (BMI) Body mass will be measured to the nearest 0.1kg and height will be measured to the nearest 0.1 cm using a clinically approved bioelectrical impedance scale and a portable stadiometer, respectively. BMI will be calculated as weight/height2 and will be converted to a BMI percentile based on WHO growth charts 3 and 6 months
Secondary Change in healthy food provision and parenting practices for healthy food As parents are active participants in the intervention The Investigators will also query their knowledge and attitudes towards healthy eating and physical activity. 3 and 6 months
Secondary Improvement in diet composition The Investigators will query the nutrition habits of participants to investigate any changes in the behaviours targeted in the workshops. A food frequency questionnaire (FFQ) taken from the ISCOLE study that was adapted from the HBSC Study will be used to query the consumption of 23 food categories in a "usual" week. The Investigators will also query breakfast consumption for weekdays and weekends. The Investigators have also created ad hoc questions on other intervention targets of snacking behaviours, fruit and vegetable intake and fizzy drink consumption. This ad hoc method has been used in other international multi-site studies. 3 and 6 months
Secondary Improvement in knowledge of physical activity and nutrition The physical activity questionnaire for adolescents (PAQ-A) [62] will be used to assess the Types and context of physical activity in order to investigate changes in the Types of sports/exercise/activities the participating child may participate in (information which is not available from the accelerometer or the majority of other validated self-report questionnaires). This questionnaire requests responses for the last 7 days by asking participants to check a list of activities for frequency of participation. This questionnaire has received support from an expert panel and has also high validity against objective measures and moderate reliability. 3 and 6 months
Secondary Improvement in HbA1c Biochemical measures (Child only) - HbA1c 3 and 6 months
Secondary Improvement in Triglycerides Biochemical measures (Child only) - Triglycerides 3 and 6 months
Secondary Improvement in Glucose Biochemical measures (Child only) - Glucose 3 and 6 months
Secondary Improvement in HDL-C Biochemical measures (Child only) HDL-C 3 and 6 months
Secondary Improvement in Total Cholesterol Biochemical measures (Child only) -Total cholesterol will be measured using a point-of-care testing (POCT) and LDL-C will be calculated. 3 and 6 months
Secondary Improvement in cardio-metabolic variables Biochemical measures (Child only) - Capillary blood samples will be taken from each child using the finger prick method. The CardioChek® system will be used as the POCT method. The CardioChek® system is a portable hand held device that requires between 15 to 40 µL capillary sample from a finger-stick for each test. The CardioChek® system is certified by the Cholesterol Reference Method Laboratory Network (CRMLN) and National Cholesterol Education Program (NCEP), is FDA-cleared, CE-marked, internationally registered, and is CLIA-waived by the Centers for Medicare & Medicaid Services, USA. 3 and 6 months
Secondary Blood Pressure (Child) Arterial blood pressure will be measured using an automated sphygmomanometer with an appropriate sized cuff while the patient is seated, and having rested quietly for 5 minutes. Three measurements will be obtained for blood pressure and an average of the last two will be used in any analysis. 3 and 6 months
Secondary Blood Pressure (Parent(s)/guardian(s)) Arterial blood pressure will be measured using an automated sphygmomanometer with an appropriate sized cuff while the patient is seated, and having rested quietly for 5 minutes. Three measurements will be obtained for blood pressure and an average of the last two will be used in any analysis. 3 and 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2